What Is It and How Does It Work?
Bempikibart is a fully human “monoclonal antibody”—a highly precise, lab-engineered protein injected under the skin.
Most treatments for severe Alopecia Areata (the autoimmune condition that causes hair to fall out in large clumps or completely) work like a heavy blanket. They suppress large portions of your immune system to stop the attack on your hair follicles. While this stops hair loss, it can also lower your body’s ability to fight off other everyday infections.
Bempikibart works through Monoclonal Antibody Blockade of Interleukin-7 Receptor Alpha (IL-7Rα) Signaling. It acts like a heat-seeking missile that targets a highly specific “master switch” in the immune system. By blocking the IL-7 and TSLP signaling pathways, the drug surgically intercepts the confused messages telling your body to attack your scalp. This precise approach allows your immune system to re-balance itself and “re-learn” how to stay calm, leaving your hair follicles free to safely grow hair again.
The Science and the Results
In a Phase 2a clinical trial called SIGNAL-AA, researchers evaluated adult patients with severe or very severe Alopecia Areata—meaning they had lost at least 50% of their scalp hair at the start of the study. Patients received subcutaneous injections of bempikibart for 24 weeks, followed by a post-treatment period where they took no medicine at all.
To measure the hair regrowth, doctors used the SALT score (Severity of Alopecia Tool). This is a standard medical scale where a score of 100 means a person has completely lost all scalp hair, and a score of 0 means they have a full, healthy head of hair.
The clear results from the study:
-
Rapid, Substantial Regrowth: At week 24, patients treated with the drug showed a 25% average reduction in their hair loss, which improved to a 27% mean reduction by week 26.
-
High-Volume Coverage: Roughly 21% of patients achieved a score of
$SALT\le20$(which means they successfully regrew 80% or more of their total scalp hair) by week 26. -
A “Remitting” Effect After Treatment Ends: The most significant finding was that even after the treatment stopped at week 24, patients did not lose their hair. Instead, they continued to grow more hair.
-
Durable Success at Week 55: At week 55—nearly seven months after their last dose—100% of the patients who responded during the trial maintained their hair or showed even deeper regrowth. Two patients demonstrated continuously improving, robust hair growth through week 55.
-
Outstanding Safety: Bempikibart was exceptionally safe. There were no severe treatment-related side effects and zero viral infections reported across the treatment group.
“If the activity of bempikibart, including the potential to induce a durable, long-term response, and the safety profile are confirmed in upcoming clinical trials, bempikibart has the potential to change the treatment paradigm of alopecia areata,” stated Jodie Morrison, CEO of Q32 Bio.
When Can You Get It?
The FDA has granted bempikibart “Fast Track” designation to speed up its clinical development. The developer, Q32 Bio, has already completed enrollment for a larger “Part B” trial of 33 patients to test a faster loading dose. Pharmacokinetic data shows this loading dose gets the drug to a steady, effective level in the body nine weeks earlier. Topline results for this next stage are expected in mid-2026. If successful, a commercially approved treatment could be in pharmacies by 2028 or 2029.
How you can benefit from this treatment now
While this drug is currently undergoing advanced clinical trials, you can benefit from this breakthrough science today by actively looking to join its open studies. Q32 Bio has initiated an Open-Label Extension (OLE) cohort for the “SIGNAL-AA” trial, allowing eligible patients to gain early access to this therapy. You can search for the “SIGNAL-AA” trial (NCT06018428) on ClinicalTrials.gov to find active study sites and see if you qualify to receive this next-generation therapy before its public release.
Read next
Whats the best shampoo for hair loss?
(https://shapiromedical.com/blog/hair-loss-research-latest-findings/)